AC Immune (ACIU) Stock Price
AC Immune Price
AC Immune (ACIU) Stock | ISIN CH0329023102 | WKN A2AR5F. The current AC Immune stock price is 1.78 CHF (2026). Revenue is 26.28 M CHF. Net income is -62.24 M CHF. The P/E ratio is -2.84. Market capitalization is 178.28 M CHF. AC Immune operates in the Health sector.
AC Immune stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AC Immune over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AC Immune stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AC Immune's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AC Immune Price |
|---|
AC Immune Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AC Immune Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M CHF) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M CHF) |
| NET INCOME (M CHF) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AC Immune generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AC Immune retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AC Immune's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AC Immune has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AC Immune's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AC Immune stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AC Immune Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AC Immune business model & stock analysis
AC Immune SWOT Analysis
Strengths
1. Strong Research and Development Capabilities: AC Immune SA possesses advanced expertise in neurodegenerative diseases, specifically in the field of Alzheimer's disease.
2. Robust Pipeline: The company has a diversified pipeline of potential therapeutics and diagnostics targeting amyloid and tau proteins, which are known to be key drivers of Alzheimer's.
3. Strategic Partnerships: AC Immune SA has established collaborations with leading pharmaceutical companies, enabling them to leverage their research capabilities and access additional resources.
Weaknesses
1. Dependency on Partnerships: The reliance on partnerships for funding and development support puts AC Immune SA at risk of potential delays or setbacks if collaborations do not meet expectations.
2. Limited Product Portfolio: As a biopharmaceutical company focused on neurodegenerative diseases, AC Immune SA's product portfolio is currently concentrated in a specific therapeutic area, limiting diversification.
3. Regulatory Challenges: Developing treatments for Alzheimer's disease poses significant regulatory hurdles and uncertainties, which may impact the approval process and timelines.
Opportunities
1. Growing Aging Population: The increasing global prevalence of Alzheimer's disease offers significant market potential for AC Immune SA's innovative therapies and diagnostics.
2. Emerging Diagnostic Technologies: Advances in diagnostic technologies may present opportunities for AC Immune SA to develop improved diagnostic tools for early detection and monitoring of Alzheimer's.
3. Potential for Combination Therapies: Collaboration with other pharmaceutical companies to develop combination therapies may enhance treatment efficacy and open new market opportunities.
Threats
1. Intense Competition: AC Immune SA faces competition from large pharmaceutical companies, biotechnology firms, and academic institutions also working on Alzheimer's disease treatments.
2. Economic and Financial Uncertainties: Market volatility, economic downturns, or lack of funding could impact AC Immune SA's ability to secure necessary investments for research and development.
3. Stringent Regulatory Environment: The stringent regulatory requirements for drug approval may result in extended timelines, increased costs, and potential failure to gain regulatory clearance.
AC Immune Eulerpool Fair Value
AC Immune historical P/E ratio, EBIT multiple, and P/S ratio
AC Immune annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AC Immune shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
AC Immune Earnings Estimates
AC Immune Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/23/2026 | -0.16CHF | 275,471CHF | 2026 Q1 |
| 3/12/2026 | -0.17CHF | 1.17 MCHF | 2025 Q4 |
| 11/14/2024 | -0.2CHF | 1.51 MCHF | 2024 Q3 |
| 3/14/2024 | 0.01CHF | 23.29 MCHF | 2023 Q4 |
| 3/20/2023 | -0.23CHF | 1.01 MCHF | 2022 Q4 |
| 10/28/2022 | -0.25CHF | 236,829CHF | 2022 Q3 |
| 7/28/2022 | -0.24CHF | 236,829CHF | 2022 Q2 |
| 4/28/2022 | -0.23CHF | 236,829CHF | 2022 Q1 |
| 3/22/2022 | 0.1CHF | 28.52 MCHF | 2021 Q4 |
| 11/8/2021 | -0.28CHF | 1.77 MCHF | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the AC Immune stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
AC Immune shareholder structure
| % | Name |
|---|---|
19.7415% | |
16.25012% | |
11.951% | |
6.40185% | |
2.944% | |
1.02042% | |
0.82494% | |
0.41001% | |
0.37916% | |
0.36232% |
AC Immune Executives and Management Board
Prof. Dr. Andrea Pfeifer
(67)Chief Executive Officer, Co-Founder, Director · since 2003
Dr. Douglas Williams
(67)Independent Chairman of the Board
Prof. Dr. Monika Buetler
(64)Independent Vice Chairman of the Board
Dr. Monica Shaw
(47)Non-Executive Independent Director
Dr. Roy Twyman
Non-Executive Independent Director
Frequently asked questions about AC Immune
The business model of AC Immune SA focuses on developing innovative therapeutics and diagnostics to prevent and treat neurodegenerative diseases, such as Alzheimer's disease. AC Immune SA employs a unique approach combining precision medicine and immunotherapy to target misfolded proteins, like tau and amyloid-beta, which play a crucial role in the progression of these diseases. By leveraging its proprietary platforms and strategic partnerships, AC Immune SA aims to bring potential disease-modifying treatments and accurate diagnostic tools to market, addressing the unmet needs in neurodegenerative disorders.
AC Immune stock
AC Immune Peer Group
AC Immune Ticker
AC Immune FIGI
All fundamentals and in-depth analysis of AC Immune
Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.